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Sympathetic overactivity in chronic heart failure (CHF) is
restrained by β-adrenergic receptor (AR) blockade improving out-
come [3]. In CHF βAR-blockade restores the sympathetic mediated
attenuation of vagal modulation of heart rate (HR) and baroreﬂex
sensitivity (BRS) [11,18,19]. Selective vs. nonselective βAR-blockers
may differ in their efﬁcacy to restore autonomic balance [22]. Only
nonselective βAR-blockade lowers systemic and cardiac norepinephr-
ine spillover, possibly by blocking prejunctional β2ARs that facilitate
norepinephrine release [1].
Nevertheless, the effect of a speciﬁc βAR-blocker may still vary
among patients, possibly mediated by β2AR genetics [10,17]. Two
common β2AR polymorphisms (Arg16Gly and Gln27Glu), affect
receptor expression and function [6,7]. The Gly16 and Glu27
polymorphisms generally being linked together form the Gly16/
Glu27 haplotype [5]. In vivo data indicate that the Gly16/Glu27
haplotype is relatively resistant to agonist-mediated desensitization of
the β2AR, leavingmore receptors available for antagonist binding with
enhanced responsiveness, as compared to the Arg16/Gln27 haplotype
[6,13].
Hypothesizing that β2AR-blockade would improve autonomic
balance particularly in patients with the Gly16/Glu27 haplotype we
determined BRS in CHF patients homozygous for either the Gly16/
Glu27 or Arg16/Gln27 haplotype during carvedilol vs. metoprolol
treatment.
Eligible patients had a stable medical condition for at least
3 months, New York Heart Association (NYHA) classiﬁcation I to III
and a left ventricular ejection fraction below 40%. Exclusion criteria
were atrial ﬁbrillation, severe aortic or mitral valve disease, severely
uncontrolled hypertension, known substance abuse or a systemic
disease that might complicate management or reduce life expec-
tancy. Patients gave written informed consent for this study
complying with the Declaration of Helsinki and approved by the
local Ethics Committee. The authors certiﬁed that they comply with
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the Principles of Ethical Publishing in the International Journal of
Cardiology [24].
Genomic DNA was isolated from peripheral blood using an Auto-
pureLS apparatus (Gentra Systems, Minneapolis, MI, USA). β2AR
genotypes at the alleles encoding for positions 16 and 27 were
determined by the big-dye terminator sequencing technique, for
which a pair of primers was designed (using Primer3; http://frodo.wi.
mit.edu/primer3/). The sequence reactions were performed using
ﬂuorescently labeled dideoxy chain terminations with a Big Dye
Terminator ABI Prism kit (Applied Biosystems, Foster City, CA, USA),
analyzed (GeneCodes Co, Ann Arbor, MI, USA) on an Applied
Biosystems automated DNA sequencer (model 3730).
Eligible patients homozygous for Gly16/Glu27 or Arg16/Gln27
were randomized to carvedilol (Eucardic, Roche, Mijdrecht, Nether-
lands) or metoprolol succinate (Selokeen ZOC, AstraZeneca, Zoeterm-
eer, Netherlands) and switched after 6 weeks. Dosages were
prescribed as equipotent to any actual βAR-blocker therapy [26]. HR
was determined one week following the initiation of each βAR-
blocker, with dosage adjustment in case of N5 beats/min change in
seated HR. At the end of both treatment-periods compliance was
assessed by tablet counting and measurements were performed.
Blood pressure (BP) and inter-beat interval were monitored by
plethysmography (Nexﬁn, BMEye, Amsterdam, Netherlands). BRS
was obtained by the sequence method [27] from 5 min beat-to-beat
systolic BP (SBP) and inter-beat interval data in supine and upright
positions. Nexﬁn CO-trek® cardiac output (CO) was estimated from
the ﬁnger pulse pressure [2]. A mixed-effects model identiﬁed effects
of βAR-blocker, posture and haplotype. Differences between haplo-
types in intra-individual BRS changes with metoprolol vs. carvedilol
were evaluated by independent t-test. Statistical signiﬁcance was set
at pb0.05, and data presented as mean±SD.
Patients were recruited between 2007 and 2009 (Fig. 1, Table 1).
Median administered daily dosages were 12.5 mg (IQR: 12.5–37.5 mg)
for carvedilol and 75 mg (IQR: 50–125 mg) for metoprolol with 99%
compliance. When supine no differences between β2AR haplotypes or
βAR-blockers were identiﬁed (Table 2). The postural decline in BRSwith
metoprolol was less evident during carvedilol treatment, particularly in
the Gly16/Glu27 patients (Gly16/Glu27: p=0.76, Arg16/Gln27: p=0.06
vs. supine). Accordingly, upright BRS was higher with carvedilol vs.
metoprolol in Gly16/Glu27, but not in Arg16/Gln27 patients (+4.3±
5.4 ms mm Hg−1 vs. +0.2±2.5 ms mm Hg−1; pb0.05, Table 2).
During carvedilol treatment upright BRS tended to be higher in Gly16/
Glu27 compared to Arg16/Gln27 patients (10.2±7.1 vs. 5.5±
3.5 msmmHg−1; p=0.06).
Although both metoprolol and carvedilol reduce mortality in CHF
[16,21], carvedilol extended median survival of CHF patients by
1.4 years as compared to metoprolol tartrate in the COMET-trial [22].
Whether the degrees of β1AR-blockade achieved in that study were
comparable was however debated [8]. In this study, metoprolol
succinate and carvedilol were HR titrated as the reduction in HR is
associated with survival beneﬁt in CHF [15].
Baroreﬂex control of HR is mainly effectuated through efferent
vagal nerve pathways with low BRS during sympathetic dominance
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[14,18]. Reduced vagal activity is associated with increased risk
of ventricular arrhythmias, and BRS has independent prognostic
value in CHF [12,20]. Carvedilol enhanced BRS in CHF patients,
whereas the effect of selective βAR-blockers is uncertain [11,19].
Blockade of the prejunctional β2AR mediated release of norepi-
nephrine likely adds to this improvement of autonomic balance
[1,11,19].
Venodilatation by the βAR agonist isoproterenol diminished in
persons homozygous for the Arg16/Gln27 haplotype, but not for the
Gly16/Glu27 haplotype [6]. In acute coronary syndrome patients
treated with (nonspeciﬁed) βAR-blockers mortality was lower in
patients homozygous for the Gly16/Glu27 compared to Arg16/Gln27
β2AR [13]. Homozygosity for the Gln27 allele in particular was
reported to negatively affect outcome in CHF [4,25], but not
conﬁrmed by others [23]. In these studies, patients were treated
with various βAR-blockers and a pharmocogenetic interaction
cannot be excluded.
An inverse relation of BRS with age in both healthy subjects [9] and
CHF patients [20] renders an effect of age in the older Gly16/Glu27
patients unlikely. Together with previous data on a beneﬁcial response
to carvedilol in CHF patients homozygous for the Glu27 allele [10,17]
our ﬁndings suggest that nonselective βAR-blocker treatment efﬁcacy
interacts with β2AR genotype. This pharmacogenetic interaction may
contribute to the improved outcomeswith either carvedilol [22] or the
Gly16/Glu27 β2AR haplotype [13,25] in cardiovascular disease.
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Table 1
Baseline characteristics of CHF patients by β2-receptor haplotype.
Gly16/Glu27
(n (%))
Arg16/Gln27
(n (%))
Age (years) 70±8 60±7⁎
Male 4 (50) 9 (69)
Cause of heart failure
Ischemic 4 (50) 10 (77)
Non-ischemic
Hypertensive CMP 0 (0) 2 (15)
Dilated CMP 4 (50) 1 (8)
NYHA classiﬁcation
I 2 (25) 4 (31)
II 4 (50) 5 (39)
III 2 (25) 4 (31)
LVEF (%) 28±11 31±4
Medical history
Hypertension 2 (25) 5 (39)
Diabetes mellitus 2 (25) 6 (46)
Hypercholesterolemia 3 (38) 4 (31)
β-Blocker before randomization
Carvedilol 3 (38) 4 (31)
Metoprolol 4 (50) 6 (46)
Bisoprolol 1 (13) 1 (8)
Nebivolol 0 (0) 2 (15)
Co-medication
RAAS-inhibitors 6 (75) 12 (92)
Loop-diuretic 6 (75) 11 (85)
Spironolactone 2 (25) 6 (46)
Vitamin K antagonists 4 (50) 8 (62)
Antiplatelet agents 5 (63) 8 (62)
Statin 6 (75) 12 (92)
Digoxin 2 (25) 1 (8)
CMP: cardiomyopathy, LVEF: left ventricular ejection fraction, NYHA: New York Heart
Association, and RAAS: renin–angiotensin–aldosterone-system.
⁎ pb0.05 vs. Gly16/Glu27.
Table 2
Cardiovascular variables.
Gly16/Glu27 Arg16/Gln27
Metoprolol Carvedilol Metoprolol Carvedilol
Supine
HR (beats min−1) 62±8 62±8 63±8 65±8
BPsys (mm Hg) 135±17 133±23 127±28 123±19
BPdia (mm Hg) 70±10 70±15 70±12 69±7
MAP (mm Hg) 92±12 91±17 89±17 87±10
SV (ml) 78±22 80±22 88±19 83±19
CO (l min−1) 4.9±1.6 5.0±1.6 5.6±1.4 5.5±1.4
SVR (dyn s cm−5) 1877±1074 1769±962 1364±314 1423±408
BRS (ms mm Hg−1) 10.0±4.7 10.9±7.3 8.7±4.6 9.2±8.0
Stand
HR (beats min−1) 74±10‡ 70±9‡ 72±9‡ 74±6‡
BPsys (mm Hg) 120±20‡ 122±26 124±29 116±25
BPdia (mm Hg) 71±9 72±9 74±12 70±11
MAP (mm Hg) 87±12 88±14 90±17 85±16
SV (ml) 58±16‡ 63±15‡ 75±20‡ 70±17‡
CO (l min−1) 4.3±1.4‡ 4.4±1.1‡ 5.3±1.3 5.1±1.3
SVR (dyn s cm−5) 1866±856 1804±678 1439±290 1480±561
BRS (ms mm Hg−1) 5.9±2.3‡ 10.2±7.1† 5.5±2.5‡ 5.5±3.5
HR: heart rate, BPsys: systolic blood pressure, BPdia: diastolic blood pressure, MAP: mean
arterial pressure, SV: stroke volume, CO: cardiac output, SVR: systemic vascular
resistance, and BRS: baroreﬂex sensitivity. Data are means±SD.
† pb0.01 vs. metoprolol.
‡ pb0.05 vs. supine.
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